首页> 美国卫生研究院文献>PLoS Clinical Trials >Mesenchymal Stem Cells in a Transgenic Mouse Model of Multiple System Atrophy: Immunomodulation and Neuroprotection
【2h】

Mesenchymal Stem Cells in a Transgenic Mouse Model of Multiple System Atrophy: Immunomodulation and Neuroprotection

机译:间质干细胞在多系统萎缩的转基因小鼠模型中:免疫调节和神经保护。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundMesenchymal stem cells (MSC) are currently strong candidates for cell-based therapies. They are well known for their differentiation potential and immunoregulatory properties and have been proven to be potentially effective in the treatment of a large variety of diseases, including neurodegenerative disorders. Currently there is no treatment that provides consistent long-term benefits for patients with multiple system atrophy (MSA), a fatal late onset α-synucleinopathy. Principally neuroprotective or regenerative strategies, including cell-based therapies, represent a powerful approach for treating MSA. In this study we investigated the efficacy of intravenously applied MSCs in terms of behavioural improvement, neuroprotection and modulation of neuroinflammation in the (PLP)-αsynuclein (αSYN) MSA model.
机译:背景间充质干细胞(MSC)目前是基于细胞疗法的强力候选药物。它们以其分化潜能和免疫调节特性而闻名,并已被证明可有效治疗多种疾病,包括神经退行性疾病。当前,尚无一种疗法可为患有多系统萎缩症(MSA)(致命的迟发性α-突触核蛋白病)的患者提供长期稳定的收益。主要的神经保护或再生策略,包括基于细胞的疗法,代表了一种治疗MSA的有效方法。在这项研究中,我们研究了在(PLP)-α突触核蛋白(αSYN)MSA模型中,行为改善,神经保护和神经炎症调节方面静脉内应用MSC的功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号